.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Chubb
Deloitte
Federal Trade Commission
Novartis
Boehringer Ingelheim
Daiichi Sankyo
US Department of Justice
Citi

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,404,717

« Back to Dashboard

Which drugs does patent 8,404,717 protect, and when does it expire?


Patent 8,404,717 protects REVLIMID and is included in one NDA. There have been three Paragraph IV challenges on Revlimid.

This patent has thirty-three patent family members in nineteen countries.

Summary for Patent: 8,404,717

Title:Methods of treating myelodysplastic syndromes using lenalidomide
Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:13/070,761
Patent Claim Types:
see list of patent claims
Use; Dosage form; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-005Dec 21, 2011RXYesNo► Subscribe► Subscribe► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-005Dec 21, 2011RXYesNo► Subscribe► SubscribeUSE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-001Dec 27, 2005RXYesNo► Subscribe► Subscribe► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-001Dec 27, 2005RXYesNo► Subscribe► SubscribeUSE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-002Dec 27, 2005RXYesNo► Subscribe► Subscribe► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-002Dec 27, 2005RXYesNo► Subscribe► SubscribeUSE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-003Jun 29, 2006RXYesNo► Subscribe► Subscribe► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-003Jun 29, 2006RXYesNo► Subscribe► SubscribeUSE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-006Jun 5, 2013RXYesNo► Subscribe► SubscribeUSE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)► Subscribe
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-004Jun 29, 2006RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,404,717

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,189,740Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes► Subscribe
8,404,716Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine► Subscribe
9,056,120Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine► Subscribe
7,863,297Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes► Subscribe
7,393,863Methods of using N-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl- -carboxamide for the treatment and management of myelodysplastic syndromes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,404,717

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1487461► Subscribe
Portugal1487461► Subscribe
New Zealand552052► Subscribe
New Zealand539533► Subscribe
MexicoPA05003888► Subscribe
South Korea20070020141► Subscribe
South Korea100711181► Subscribe
South Korea20050053769► Subscribe
Japan2013526525► Subscribe
Japan2007045839► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
UBS
Julphar
Chinese Patent Office
Medtronic
Cipla
US Department of Justice
Fish and Richardson
Fuji
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot